Pay in 4 interest-free payments of $7.40 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
As GLP-1 innovations expand into new therapeutic areas and formats, partnering with Redbock for your clinical trial support, pharmacovigilance, and device engineering resourcing needs can drive your success
Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial
No patient had had a change in any of these medications 6 weeks prior to participating in this study
Stop using GLP-1s two months before becoming pregnant
Whilst some supplements (such as certain probiotics or omega-3 fatty acids) show promise in research settings, evidence remains preliminary
This study included 78 patients who received 10 mcg of subcutaneous lixisenatide once daily for 14 days, followed by 20 mcg once daily for the remainder of the 12-month period, and 78 patients who received placebo
